Contineum Therapeutics, Inc.CContineum Therapeutics, Inc.

Contineum Therapeutics, Inc.

14.15USDR
+0.09+0.64%
As of today at 15:11 UTC
USD
No trades
See on Supercharts

CTNM fundamentals

Contineum Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss

The annual and quarterly earnings report below will help you understand the performance of CTNM.

Q4 '22
Q1 '23
Q2 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−17.00 M‬‬
‪0.00‬
‪‪17.00 M‬‬
‪‪34.00 M‬‬
‪‪51.00 M‬‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
TTM
Total revenueYoY growth
‪0.00‬
‪0.00‬
‪‪50.00 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
−100.00%
‪‪−81.00 K‬‬
‪‪−73.00 K‬‬
‪‪−42.00 K‬‬
‪‪−37.00 K‬‬
‪‪−61.00 K‬‬
‪‪−60.00 K‬‬
‪‪−62.00 K‬‬
‪‪−220.00 K‬‬
Gross profitYoY growth
‪‪−81.00 K‬‬
‪‪−73.00 K‬‬
‪‪49.96 M‬‬
‪‪−37.00 K‬‬
‪‪−61.00 K‬‬
+24.69%
‪‪−60.00 K‬‬
+17.81%
‪‪−62.00 K‬‬
−100.12%
‪‪−220.00 K‬‬
‪‪−5.37 M‬‬
‪‪−5.04 M‬‬
‪‪−11.02 M‬‬
‪‪−9.64 M‬‬
‪‪−9.87 M‬‬
‪‪−10.88 M‬‬
‪‪−12.91 M‬‬
‪‪−43.30 M‬‬
‪‪−5.45 M‬‬
‪‪−5.12 M‬‬
‪‪38.94 M‬‬
‪‪−9.68 M‬‬
‪‪−9.93 M‬‬
−82.24%
‪‪−10.94 M‬‬
−113.96%
‪‪−12.97 M‬‬
−133.32%
‪‪−43.52 M‬‬
‪‪−2.06 M‬‬
‪‪291.00 K‬‬
‪‪3.36 M‬‬
‪‪1.75 M‬‬
‪‪1.51 M‬‬
‪‪1.93 M‬‬
‪‪2.71 M‬‬
‪‪7.90 M‬‬
Pretax incomeYoY growth
‪‪−7.51 M‬‬
‪‪−4.82 M‬‬
‪‪42.29 M‬‬
‪‪−7.93 M‬‬
‪‪−8.42 M‬‬
−12.05%
‪‪−9.01 M‬‬
−86.75%
‪‪−10.27 M‬‬
−124.28%
‪‪−35.62 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪−729.00 K‬‬
‪‪161.00 K‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪161.00 K‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪−7.51 M‬‬
‪‪−4.82 M‬‬
‪‪41.56 M‬‬
‪‪−7.77 M‬‬
‪‪−8.42 M‬‬
‪‪−9.01 M‬‬
‪‪−10.27 M‬‬
‪‪−35.46 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
Net incomeYoY growth
‪‪−7.51 M‬‬
‪‪−4.82 M‬‬
‪‪41.56 M‬‬
‪‪−7.77 M‬‬
‪‪−8.42 M‬‬
−12.05%
‪‪−9.01 M‬‬
−86.75%
‪‪−10.27 M‬‬
−124.70%
‪‪−35.46 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪−6.58 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪−6.58 M‬‬
‪‪−7.51 M‬‬
‪‪−4.82 M‬‬
‪‪41.56 M‬‬
‪‪−1.19 M‬‬
‪‪−8.42 M‬‬
‪‪−9.01 M‬‬
‪‪−10.27 M‬‬
‪‪−28.89 M‬‬
‪−0.30‬
‪−0.19‬
‪1.62‬
‪−0.05‬
‪−0.33‬
−9.47%
‪−0.35‬
−86.77%
‪−0.40‬
−124.69%
‪−1.12‬
‪−0.30‬
‪−0.19‬
‪1.62‬
‪−0.05‬
‪−0.33‬
−9.47%
‪−0.35‬
−86.77%
‪−0.40‬
−124.69%
‪−1.12‬
‪‪25.13 M‬‬
‪‪25.72 M‬‬
‪‪25.72 M‬‬
‪‪25.13 M‬‬
‪‪25.72 M‬‬
‪‪25.72 M‬‬
‪‪25.74 M‬‬
‪‪25.13 M‬‬
‪‪25.72 M‬‬
‪‪25.72 M‬‬
‪‪25.13 M‬‬
‪‪25.72 M‬‬
‪‪25.72 M‬‬
‪‪25.74 M‬‬
EBITDAYoY growth
‪‪−5.37 M‬‬
‪‪−5.04 M‬‬
‪‪38.98 M‬‬
‪‪−9.64 M‬‬
‪‪−9.87 M‬‬
−83.85%
‪‪−10.88 M‬‬
−115.87%
‪‪−12.91 M‬‬
−133.13%
‪‪−43.30 M‬‬
EBITYoY growth
‪‪−5.45 M‬‬
‪‪−5.12 M‬‬
‪‪38.94 M‬‬
‪‪−9.68 M‬‬
‪‪−9.93 M‬‬
−82.24%
‪‪−10.94 M‬‬
−113.96%
‪‪−12.97 M‬‬
−133.32%
‪‪−43.52 M‬‬
‪‪−5.45 M‬‬
‪‪−5.12 M‬‬
‪‪−11.06 M‬‬
‪‪−9.68 M‬‬
‪‪−9.93 M‬‬
‪‪−10.94 M‬‬
‪‪−12.97 M‬‬
‪‪−43.52 M‬‬